Skip to main content
. Author manuscript; available in PMC: 2019 Jul 8.
Published in final edited form as: Pigment Cell Melanoma Res. 2018 Dec 16;32(2):303–314. doi: 10.1111/pcmr.12751

Figure 2. RMEL3 lncRNA levels decrease in BRAFV600E mutant melanoma cells after treatment with BRAF and MEK inhibitors.

Figure 2.

(A - D) RT-qPCR expression analyses of (A, B) RMEL3 lncRNA and (C, D) FOXD3 (positive control) in melanoma cell lines treated with the BRAF inhibitor vemurafenib (PLX4032) (1 μM, 6 h or 10 μM, 48 h) and respective controls (vehicle), as indicated. (E) Western blot analysis for phosphorylated ERK (pERK) and total ERK (tERK) in total protein lysates from melanoma cells treated with BRAF inhibitor (1 μM, 6 h or 10 μM, 48 h) or vehicle. (F) RT-qPCR expression analysis of RMEL3 in UACC-62 melanoma cell line treated with the MEK inhibitor PD98059 (25 μM) or vehicle for 48 hr, and corresponding Western blot analysis for phosphorylated ERK (pERK) and total ERK (tERK) in total protein lysates of treated and control melanoma cells. For all RT-qPCR analyses, relative expression was calculated according to 2−ΔΔCT method using TBP (Tata-box binding protein) as endogenous control and the normalized Ct of the sample treated with the vehicle alone as reference. Error bars represent SEM of 3 independent experiments. *p < 0.05; **p < 0.005; ***p < 0.0005; ****p < 0.00005. Asterisks indicate statistically significant differences between groups based on unpaired parametric Student’s t test